Clinical Studies: Treatment of chronic hepatitis delta with pegylated interferon- alpha 2b
Chronic hepatitis D is difficult to treat. The present pilot study investigated the efficacy and tolerability of pegylated (PEG)-interferon (IFN)- alpha 2b in chronic hepatitis D. Patients and Methods: Twelve patients with chronic hepatitis D were prospectively treated with 1.5 mu g-kg PEG-IFN- alph...
Gespeichert in:
| Veröffentlicht in: | Liver international 2006-09, Vol.26 (7), p.805-810 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 810 |
|---|---|
| container_issue | 7 |
| container_start_page | 805 |
| container_title | Liver international |
| container_volume | 26 |
| creator | Erhardt, Andreas Gerlich, Wolfram Starke, Christine Wend, Ulrike Donner, Andreas Sagir, Abdurrahman Heintges, Tobias Haeussinger, Dieter |
| description | Chronic hepatitis D is difficult to treat. The present pilot study investigated the efficacy and tolerability of pegylated (PEG)-interferon (IFN)- alpha 2b in chronic hepatitis D. Patients and Methods: Twelve patients with chronic hepatitis D were prospectively treated with 1.5 mu g-kg PEG-IFN- alpha 2b for 48 weeks and followed for 24 weeks. Sustained response (SR) was defined as undetectable hepatitis delta virus (HDV) RNA by reverse transcriptase-polymerase chain reaction and normalization of alanine aminotransferase (ALT) at 6 months after treatment. Investigations included HDV RNA kinetics, determination of hepatitis B virus (HBV) and HDV genotypes and histological evaluation. Results: An SR was achieved in two out of 12 of patients (17%). The negative predictive value of a less than 3 log HDV RNA decrease at month 6 was 100%. The positive predictive value of a more than 3 log HDV RNA decrease at month 6 was 67%. A marked ALT reduction at the end of treatment was observed in responders and nonresponders. Ishak histological score was comparable at baseline and significantly improved in responders compared with nonresponders at the end of follow-up (13.5 vs. 8.0; P |
| doi_str_mv | 10.1111/j.1478-3231.2006.01279.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_19853998</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19853998</sourcerecordid><originalsourceid>FETCH-proquest_miscellaneous_198539983</originalsourceid><addsrcrecordid>eNqNirtOw0AQRVeISATCP0xF580-CPamjYLSx1Uaa7DHeKP1A-9Ygb-PC5Q6tzlXOkcI0Erqeeuz1O9pllhjtTRKfUilTerk74NY3sTj7Rv7JJ5jPCulndvopTjtgu98iQGOPFWe4hbykZBb6hj6Gspm7GcPDQ3Inn2EigIjXDw3MND3X0CmCnzHNNY0twlgGBoE87USixpDpNd_voi3z32-OyTD2P9MFLlofSwpBOyon2KhXbaxzmX27vAKlCxOCg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19853998</pqid></control><display><type>article</type><title>Clinical Studies: Treatment of chronic hepatitis delta with pegylated interferon- alpha 2b</title><source>Wiley Online Library All Journals</source><creator>Erhardt, Andreas ; Gerlich, Wolfram ; Starke, Christine ; Wend, Ulrike ; Donner, Andreas ; Sagir, Abdurrahman ; Heintges, Tobias ; Haeussinger, Dieter</creator><creatorcontrib>Erhardt, Andreas ; Gerlich, Wolfram ; Starke, Christine ; Wend, Ulrike ; Donner, Andreas ; Sagir, Abdurrahman ; Heintges, Tobias ; Haeussinger, Dieter</creatorcontrib><description>Chronic hepatitis D is difficult to treat. The present pilot study investigated the efficacy and tolerability of pegylated (PEG)-interferon (IFN)- alpha 2b in chronic hepatitis D. Patients and Methods: Twelve patients with chronic hepatitis D were prospectively treated with 1.5 mu g-kg PEG-IFN- alpha 2b for 48 weeks and followed for 24 weeks. Sustained response (SR) was defined as undetectable hepatitis delta virus (HDV) RNA by reverse transcriptase-polymerase chain reaction and normalization of alanine aminotransferase (ALT) at 6 months after treatment. Investigations included HDV RNA kinetics, determination of hepatitis B virus (HBV) and HDV genotypes and histological evaluation. Results: An SR was achieved in two out of 12 of patients (17%). The negative predictive value of a less than 3 log HDV RNA decrease at month 6 was 100%. The positive predictive value of a more than 3 log HDV RNA decrease at month 6 was 67%. A marked ALT reduction at the end of treatment was observed in responders and nonresponders. Ishak histological score was comparable at baseline and significantly improved in responders compared with nonresponders at the end of follow-up (13.5 vs. 8.0; P<0.02). Conclusion: The present study indicates that PEG-IFN- alpha 2b is a promising treatment option in chronic hepatitis D. Nonresponders could be identified by a less than 3 log decrease of HDV RNA at 6 months of treatment.</description><identifier>ISSN: 1478-3223</identifier><identifier>EISSN: 1478-3231</identifier><identifier>DOI: 10.1111/j.1478-3231.2006.01279.x</identifier><language>eng</language><subject>Hepatitis B virus ; Hepatitis D virus</subject><ispartof>Liver international, 2006-09, Vol.26 (7), p.805-810</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids></links><search><creatorcontrib>Erhardt, Andreas</creatorcontrib><creatorcontrib>Gerlich, Wolfram</creatorcontrib><creatorcontrib>Starke, Christine</creatorcontrib><creatorcontrib>Wend, Ulrike</creatorcontrib><creatorcontrib>Donner, Andreas</creatorcontrib><creatorcontrib>Sagir, Abdurrahman</creatorcontrib><creatorcontrib>Heintges, Tobias</creatorcontrib><creatorcontrib>Haeussinger, Dieter</creatorcontrib><title>Clinical Studies: Treatment of chronic hepatitis delta with pegylated interferon- alpha 2b</title><title>Liver international</title><description>Chronic hepatitis D is difficult to treat. The present pilot study investigated the efficacy and tolerability of pegylated (PEG)-interferon (IFN)- alpha 2b in chronic hepatitis D. Patients and Methods: Twelve patients with chronic hepatitis D were prospectively treated with 1.5 mu g-kg PEG-IFN- alpha 2b for 48 weeks and followed for 24 weeks. Sustained response (SR) was defined as undetectable hepatitis delta virus (HDV) RNA by reverse transcriptase-polymerase chain reaction and normalization of alanine aminotransferase (ALT) at 6 months after treatment. Investigations included HDV RNA kinetics, determination of hepatitis B virus (HBV) and HDV genotypes and histological evaluation. Results: An SR was achieved in two out of 12 of patients (17%). The negative predictive value of a less than 3 log HDV RNA decrease at month 6 was 100%. The positive predictive value of a more than 3 log HDV RNA decrease at month 6 was 67%. A marked ALT reduction at the end of treatment was observed in responders and nonresponders. Ishak histological score was comparable at baseline and significantly improved in responders compared with nonresponders at the end of follow-up (13.5 vs. 8.0; P<0.02). Conclusion: The present study indicates that PEG-IFN- alpha 2b is a promising treatment option in chronic hepatitis D. Nonresponders could be identified by a less than 3 log decrease of HDV RNA at 6 months of treatment.</description><subject>Hepatitis B virus</subject><subject>Hepatitis D virus</subject><issn>1478-3223</issn><issn>1478-3231</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNqNirtOw0AQRVeISATCP0xF580-CPamjYLSx1Uaa7DHeKP1A-9Ygb-PC5Q6tzlXOkcI0Erqeeuz1O9pllhjtTRKfUilTerk74NY3sTj7Rv7JJ5jPCulndvopTjtgu98iQGOPFWe4hbykZBb6hj6Gspm7GcPDQ3Inn2EigIjXDw3MND3X0CmCnzHNNY0twlgGBoE87USixpDpNd_voi3z32-OyTD2P9MFLlofSwpBOyon2KhXbaxzmX27vAKlCxOCg</recordid><startdate>20060901</startdate><enddate>20060901</enddate><creator>Erhardt, Andreas</creator><creator>Gerlich, Wolfram</creator><creator>Starke, Christine</creator><creator>Wend, Ulrike</creator><creator>Donner, Andreas</creator><creator>Sagir, Abdurrahman</creator><creator>Heintges, Tobias</creator><creator>Haeussinger, Dieter</creator><scope>7T5</scope><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>20060901</creationdate><title>Clinical Studies: Treatment of chronic hepatitis delta with pegylated interferon- alpha 2b</title><author>Erhardt, Andreas ; Gerlich, Wolfram ; Starke, Christine ; Wend, Ulrike ; Donner, Andreas ; Sagir, Abdurrahman ; Heintges, Tobias ; Haeussinger, Dieter</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_miscellaneous_198539983</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Hepatitis B virus</topic><topic>Hepatitis D virus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Erhardt, Andreas</creatorcontrib><creatorcontrib>Gerlich, Wolfram</creatorcontrib><creatorcontrib>Starke, Christine</creatorcontrib><creatorcontrib>Wend, Ulrike</creatorcontrib><creatorcontrib>Donner, Andreas</creatorcontrib><creatorcontrib>Sagir, Abdurrahman</creatorcontrib><creatorcontrib>Heintges, Tobias</creatorcontrib><creatorcontrib>Haeussinger, Dieter</creatorcontrib><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Liver international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Erhardt, Andreas</au><au>Gerlich, Wolfram</au><au>Starke, Christine</au><au>Wend, Ulrike</au><au>Donner, Andreas</au><au>Sagir, Abdurrahman</au><au>Heintges, Tobias</au><au>Haeussinger, Dieter</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical Studies: Treatment of chronic hepatitis delta with pegylated interferon- alpha 2b</atitle><jtitle>Liver international</jtitle><date>2006-09-01</date><risdate>2006</risdate><volume>26</volume><issue>7</issue><spage>805</spage><epage>810</epage><pages>805-810</pages><issn>1478-3223</issn><eissn>1478-3231</eissn><abstract>Chronic hepatitis D is difficult to treat. The present pilot study investigated the efficacy and tolerability of pegylated (PEG)-interferon (IFN)- alpha 2b in chronic hepatitis D. Patients and Methods: Twelve patients with chronic hepatitis D were prospectively treated with 1.5 mu g-kg PEG-IFN- alpha 2b for 48 weeks and followed for 24 weeks. Sustained response (SR) was defined as undetectable hepatitis delta virus (HDV) RNA by reverse transcriptase-polymerase chain reaction and normalization of alanine aminotransferase (ALT) at 6 months after treatment. Investigations included HDV RNA kinetics, determination of hepatitis B virus (HBV) and HDV genotypes and histological evaluation. Results: An SR was achieved in two out of 12 of patients (17%). The negative predictive value of a less than 3 log HDV RNA decrease at month 6 was 100%. The positive predictive value of a more than 3 log HDV RNA decrease at month 6 was 67%. A marked ALT reduction at the end of treatment was observed in responders and nonresponders. Ishak histological score was comparable at baseline and significantly improved in responders compared with nonresponders at the end of follow-up (13.5 vs. 8.0; P<0.02). Conclusion: The present study indicates that PEG-IFN- alpha 2b is a promising treatment option in chronic hepatitis D. Nonresponders could be identified by a less than 3 log decrease of HDV RNA at 6 months of treatment.</abstract><doi>10.1111/j.1478-3231.2006.01279.x</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1478-3223 |
| ispartof | Liver international, 2006-09, Vol.26 (7), p.805-810 |
| issn | 1478-3223 1478-3231 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_19853998 |
| source | Wiley Online Library All Journals |
| subjects | Hepatitis B virus Hepatitis D virus |
| title | Clinical Studies: Treatment of chronic hepatitis delta with pegylated interferon- alpha 2b |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T13%3A31%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20Studies:%20Treatment%20of%20chronic%20hepatitis%20delta%20with%20pegylated%20interferon-%20alpha%202b&rft.jtitle=Liver%20international&rft.au=Erhardt,%20Andreas&rft.date=2006-09-01&rft.volume=26&rft.issue=7&rft.spage=805&rft.epage=810&rft.pages=805-810&rft.issn=1478-3223&rft.eissn=1478-3231&rft_id=info:doi/10.1111/j.1478-3231.2006.01279.x&rft_dat=%3Cproquest%3E19853998%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=19853998&rft_id=info:pmid/&rfr_iscdi=true |